美國CDC指Moderna保護力較輝瑞佳 FDA倡65歲長者打加強劑
美國疾控中心(CDC)表示,莫德納(Moderna)新冠疫苗較輝瑞或強生新冠疫苗有較佳的保護力,在接種4個月後,保護力出現更大的差距。
CDC稱,有關報告是追蹤3700個3月完成接種者至8月中的情況後撰寫。結果顯示,莫德納疫苗對於接種者不出現嚴重病徵以致須入院方面的保護率是93%,輝瑞疫苗是88%,強生疫苗是71%。
另外,美國食品及藥物管理局(FDA)豁下疫苗顧問委員會建議,應爲65歲以上人士,接種輝瑞/BioNTech新冠疫苗加強劑,但不贊同爲普羅民衆接種加強針的計劃,表示要待有更多數據後,才作出相關決定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.